Navigation Links
Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product
Date:7/15/2009

CARY, N.C., July 15 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that it has submitted a regulatory filing with the U.S. Food and Drug Administration (FDA) for an extended-release antitussive product (CRTX 067) that, if approved, would compete directly in the large prescription antitussive market. Depending upon the timing of FDA approval, Cornerstone expects that the product could be commercially available in 2011.

Cough is one of the most common symptoms prompting patients to see their primary care physician. According to data derived from Source((R)) Pharmaceutical Audit Suite, January-December 2008, Wolters Kluwer Health, in 2008, there were over 30 million prescriptions and nearly $1 billion dollars in sales generated for oral antitussives; however, most oral antitussive products that are currently marketed are in an immediate-release formulation (over 25 million prescriptions annually) requiring dosing every four to six hours, which can be inconvenient and adversely affect patient compliance. Cornerstone believes that its antitussive product may improve patient compliance by providing more convenient twice-daily dosing.

"This is an important regulatory submission for Cornerstone, as it is the first of several applications for which we plan to seek FDA approval over the next few years," said Craig Collard, President and CEO of Cornerstone. "This antitussive product is an important part of our overall corporate strategy to compete in the prescription Cough and Cold Preparations market, which represents over 40 million prescriptions annually."

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with four additional regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force, which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

Statements in this press release regarding the progress and timing of our product development programs, including their related trials and regulatory approvals; our future opportunities; our strategy, future operations, financial position, future revenues and projected costs; our management's prospects, plans and objectives; and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Any statements that are not statements of historical fact (including, without limitation, statements containing the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including risks relating to our ability to develop and maintain the necessary sales, marketing, supply chain, distribution and manufacturing capabilities to commercialize our products, including difficulties relating to the manufacture of Zyflo CR((R)) tablets; the possibility that the Food and Drug Administration (the FDA) will take enforcement action against us or one or more of our marketed drugs that do not have FDA-approved marketing applications; patient, physician and third-party payor acceptance of our products as safe and effective therapeutic products; our heavy dependence on the commercial success of a relatively small number of currently marketed products; our ability to maintain regulatory approvals to market and sell our products that do have FDA approved marketing applications; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to satisfy FDA and other regulatory requirements; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in Item 1A (Risk Factors) of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on May 7, 2009 and other filings that we make with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make, except that in particular circumstances as specifically indicated we may address the potential impact of our proposed transaction with Chiesi Farmaceutici SpA. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this release.

Zyflo CR((R)) is a registered trademark of Cornerstone Therapeutics Inc. Source((R)) Pharmaceutical Audit Suite is a registered trademark of Wolters Kluwer Health.

    Investor Relations Contacts:
    FD
    Evan Smith/Brian Ritchie
    212-850-5600
    evan.smith@fd.com/brian.ritchie@fd.com

    Media Relations Contact:
    FD
    Robert Stanislaro
    212-850-5600
    robert.stanislaro@fd.com


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cornerstone Therapeutics Joins the Russell 3000(R) Index
2. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Issuance and Sale of Stock
3. TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform
4. Cornerstone Therapeutics Announces Management Change
5. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
6. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
7. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
8. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
9. Cornerstone Therapeutics Announces New Board of Directors
10. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
11. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Florida Hospital presents Heart Health Awareness night ... Louis Blues at the Amalie Arena. The puck drops at 6:00pm, but fans will ... MEGA Heart, prior to the game. The MEGA Heart will be located on Ford ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... has been gearing up for their simultaneous grand openings in March. All seven ... now that you’re probably wondering, is reversing diabetes possible? According to this 2011 ...
(Date:2/11/2016)... Plantation, Fla. (PRWEB) , ... February 11, 2016 ... ... CareTRAK™, an unparalleled clinical decision support technology, with highly adaptable algorithms, has ... cases. When a patient has signs and symptoms consistent with Zikas and a ...
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield Insurance Group in ... to assist the people of their local community. The agency pledges to select ... leaders. Their hope is to bring awareness to important local causes with fundraising ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dickinson Insurance & Financial Services continues their ... fundraiser in support of a local boy named Barrett, who has been fighting ALL ... to, and rally support for, all local families dealing with childhood cancer. Information on ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... --  Health 2.0 , the premiere showcase and catalyst ... " 10 Year Global Retrospective ", a platform to ... ten years.   --> ... served as the preeminent thought-leader in the health tech ... companies, innovators, and patient-activists through an array of events ...
(Date:2/11/2016)... , Feb. 11, 2016 AAIPharma ... provider of custom manufacturing and development services for ... sterile fill-finish capabilities and capacity in its ... in demand has driven several recent investments. ... it had one filling line with small-scale lyophilization. ...
(Date:2/11/2016)... ANKENY, Iowa , 11 de fevereiro de ... a inauguração de sua fábrica de soroalbumina bovina ... Nova Zelândia. A fábrica fica na Ilha Norte ... Loop "), desenvolvido e estabelecido na fábrica da ... Iowa . O projeto e instalação dos ...
Breaking Medicine Technology: